Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

Draft:Perspective Therapeutics

From Wikipedia, the free encyclopedia

Perspective Therapeutics, Inc. is an American clinical-stage radiopharmaceutical company headquartered in Seattle, Washington. It develops targeted alpha-particle treatments for cancer based on lead-212, along with lead-203 compounds for diagnostic imaging.[1][2][3] The company is traded on the NYSE American under the ticker symbol CATX.[2]

History

[edit]

Viewpoint Molecular Targeting was a radiopharmaceutical developer based in Coralville, Iowa, that originated as a University of Iowa spinout.[4] In September 2022, Viewpoint agreed to merge with Isoray, a publicly traded maker of cesium-131 brachytherapy seeds. The merger closed in February 2023, with Viewpoint becoming a wholly owned subsidiary of Isoray; Isoray then changed its name to Perspective Therapeutics and its stock symbol from ISR to CATX.[5][6]

In December 2023, Perspective agreed to sell the cesium-131 business of its Isoray subsidiary to GT Medical Technologies. The transaction closed in April 2024.[7][8][2]

Research and development

[edit]

Lead-212 decays through alpha-emitting daughter isotopes. Lead-203 can be attached to a corresponding targeting compound for SPECT imaging.[9][3] A 2025 paper reported initial clinical experience in 12 patients with metastatic neuroendocrine tumors, who underwent lead-203 imaging followed, where eligible, by lead-212 treatment.[3]

As of September 2026, Perspective's clinical programs included lead (²¹²Pb) bamzireotide navoxetan (VMT-α-NET), which targets somatostatin receptor 2 in neuroendocrine tumors;[10][11] lead (²¹²Pb) lapemelanotide zapixetan (VMT01), which targets melanocortin 1 receptor in melanoma;[10][12][13] and PSV359, which targets fibroblast activation protein alpha in solid tumors.[14] The studies were in Phase 1/2a development.[2][15]

Perspective arranged for Bristol Myers Squibb to supply nivolumab for a VMT01 combination study.[16] In September 2026, it announced a similar drug-supply arrangement with Merck for a planned PSV359 and pembrolizumab combination arm.[17]

Manufacturing

[edit]

Perspective obtains thorium-228 under a U.S. Department of Energy supply agreement and uses a generator system to produce lead-212 for its investigational treatments.[2] In March 2024, it acquired the assets and associated lease of a radiopharmaceutical manufacturing facility in Somerset, New Jersey.[15] It has supplied clinical trials from manufacturing sites in Coralville, Iowa, and Somerset, New Jersey.[15] The company has cited lead-212's short half-life as a reason for developing a geographically distributed production network.[18] As of 2026, the company was expanding this network with additional sites in the Chicago and Los Angeles metropolitan areas, with the Chicago-area facility expected to be completed in 2027.[15]

References

[edit]
  1. ↑ Samorodnitsky, Dan (June 6, 2025). "Perspective Therapeutics Brings Energy to the Radiopharma World". BioSpace. https://www.biospace.com/drug-development/perspective-therapeutics-brings-energy-to-the-radiopharma-world
  2. 1 2 3 4 5 Perspective Therapeutics, Inc. Annual Report on Form 10-K for the year ended December 31, 2025 (filed 2026). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/728387/000072838726000004/catx-20251231.htm
  3. 1 2 3 Michler, Enrico; et al. (2025). "[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience". European Journal of Nuclear Medicine and Molecular Imaging 52: 4171–4183. doi:10.1007/s00259-025-07269-0.
  4. ↑ University of Iowa, Office of the Vice President for Research (August 31, 2016). "UI-spinout Viewpoint Molecular Targeting finalist in national university startup competition". https://research.uiowa.edu/news/2016/08/ui-spinout-viewpoint-molecular-targeting-finalist-national-university-startup
  5. ↑ Isoray, Inc. Current Report on Form 8-K, filed February 6, 2023 (completion of the merger with Viewpoint Molecular Targeting on February 3, 2023). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/728387/000143774923002543/isr20230204_8k.htm
  6. ↑ Lohman, John (February 8, 2023). "Medtech companies merge to form Perspective Therapeutics". Corridor Business Journal. https://corridorbusiness.com/medtech-companies-merge-to-form-perspective-therapeutics/
  7. ↑ "GT Medical Technologies inks supply deal with Perspective Therapeutics". AuntMinnie. December 12, 2023. https://www.auntminnie.com/clinical-news/radiation-oncology-therapy/article/15660040/gt-medical-technologies-inks-supply-deal-with-perspective-therapeutics
  8. ↑ "GT Medical completes acquisition of Isoray Medical cesium-131 assets". AuntMinnie. April 15, 2024. https://www.auntminnie.com/clinical-news/radiation-oncology-therapy/article/15668623/gt-medical-completes-acquisition-of-isoray-medical-cesium131-assets
  9. ↑ Scaffidi-Muta, Jarred Michael; Abell, Andrew David (2025). "212Pb in targeted radionuclide therapy: a review". EJNMMI Radiopharmacy and Chemistry 10. doi:10.1186/s41181-025-00362-7.
  10. 1 2 World Health Organization (2025). "International Nonproprietary Names for Pharmaceutical Substances (INN): Recommended INN List 93". WHO Drug Information. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl93.pdf
  11. ↑ ClinicalTrials.gov. "Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors". NCT05636618. https://clinicaltrials.gov/study/NCT05636618
  12. ↑ Orcutt, Karen D.; et al. (2022). "Dosimetry of [212Pb]VMT01, a MC1R-Targeted Alpha Therapeutic Compound, and Effect of Free 208Tl on Tissue Absorbed Doses". Molecules 27 (18): 5831. doi:10.3390/molecules27185831.
  13. ↑ ClinicalTrials.gov. "MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma". NCT05655312. https://clinicaltrials.gov/study/NCT05655312
  14. ↑ ClinicalTrials.gov. "Lead-212 PSV359 Therapy for Patients With Solid Tumors". NCT06710756. https://clinicaltrials.gov/study/NCT06710756
  15. 1 2 3 4 Perspective Therapeutics, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/728387/000119312526342512/catx-20260630.htm
  16. ↑ Perspective Therapeutics (March 18, 2024). "Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate VMT01 with Nivolumab". https://perspectivetherapeutics.com/pr/perspective-therapeutics-announces-clinical-collaboration-agreement-with-bristol-myers-squibb-to-evaluate-212pbvmt01-in-combination-with-nivolumab-in-mc1rpositive-metastatic-melanoma
  17. ↑ Perspective Therapeutics (September 14, 2026). "Clinical Collaboration and Supply Agreement with Merck to Evaluate PSV359 with Pembrolizumab". https://perspectivetherapeutics.com/pr/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pbpsv359-in-combination-with-keytruda-pembrolizumab-in-fap-positive-solid-tumors
  18. ↑ Lundin, Andy (September 8, 2026). "Radiopharma’s growing pipeline puts capacity to the test". Pharma Manufacturing. https://www.pharmamanufacturing.com/facilities/facility-design-management/article/55403416/radiopharmas-growing-pipeline-puts-capacity-to-the-test
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Perspective_Therapeutics&oldid=1377747408"